Home LiteratureArticle Details
PMID: 8485621 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.

British journal of pharmacology ·Vol. 108 ·No. 4 ·1993-04-00 ·Pages 1117-24

Semba J, Curzon G, Patsalos PN

Abstract

1. The kinetics and metabolism of milacemide have been studied in an animal model which allows the simultaneous investigation of the temporal inter-relationships of drugs and metabolites in blood (pharmacokinetics) and cerebrospinal fluid (CSF, neuropharmacokinetics) in individual freely moving rats. 2. Milacemide dose-dependently increased CSF glycine and glycinamide (intermediary metabolite) concentrations. This confirms that milacemide is a CNS glycine prodrug. 3. Pretreatment with L-deprenyl (2 mg kg-1), a specific inhibitor of monoamine oxidase type B (MAO-B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF. Tmax and t1/2 were significantly increased and Cmax and AUC values were decreased for glycinamide compared to controls. Pretreatment with clorgyline (5 mg kg-1), a specific inhibitor of MAO-type A, only moderately decreased glycinamide Cmax and AUC values. 4. After milacemide administration (100, 200 and 400 mg kg-1, i.p.) serum and CSF milacemide concentrations rose linearly and dose-dependently. Serum glycinamide concentrations exhibited small dose-dependent rises but these were not linearly related. In contrast, CSF glycinamide concentrations rose linearly and dose-dependently with Cmax values 2.5, 3.2 and 4.1 times greater than the corresponding values for serum glycinamide after giving 100, 200 and 400 mg kg-1 respectively of milacemide. 5. Serum glycine concentrations were unaffected but CSF concentrations increased dose-dependently and these were significant at the higher milacemide doses (200 and 400 mg kg-1). Animals given 400 mg kg-1 milacemide had glycine values which were still significantly elevated 7 h later. 6. In conclusion, serum milacemide rapidly enters and equilibrates with the CNS compartment where it is metabolised primarily by MAO-B to glycinamide and finally to glycine. Metabolism in the peripheral compartment is negligible.

MeSH Terms
Acetamides/blood,cerebrospinal fluid,pharmacokinetics Animals Anticonvulsants/blood,cerebrospinal fluid,pharmacokinetics Chromatography, High Pressure Liquid Glycine/analogs & derivatives,blood,cerebrospinal fluid Half-Life Male Monoamine Oxidase Inhibitors/pharmacology Rats Rats, Sprague-Dawley Spectrophotometry, Ultraviolet
Chemicals
Acetamides Anticonvulsants Monoamine Oxidase Inhibitors milacemide glycine amide Glycine
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Semba J
Epilepsy Research Group, University Department of Clinical Neurology, Queen Square, London.
Curzon G
Patsalos P N
References (39)
39 references, click to expand
  1. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.
    J Pharmacol Exp Ther. 1988 Mar;244(3):912-8 PMID: 2908048
  2. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.
    Br J Pharmacol. 1981 May;73(1):55-64 PMID: 7284698
  3. An NMDA intervention strategy in schizophrenia with "low-dose" milacemide.
    Clin Neuropharmacol. 1991 Jun;14(3):268-72 PMID: 1829980
  4. Anticonvulsant activity of milacemide.
    Arch Int Pharmacodyn Ther. 1983 Dec;266(2):239-49 PMID: 6667068
  5. Drug metabolizing enzymes in the brain and cerebral microvessels.
    Brain Res Brain Res Rev. 1991 Jan-Apr;16(1):65-82 PMID: 1907518
  6. Glutamatergic therapy of Huntington's chorea.
    Clin Neuropharmacol. 1992 Apr;15(2):148-51 PMID: 1350513
  7. Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier.
    J Neurochem. 1971 Apr;18(4):613-20 PMID: 5581576
  8. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.
    Clin Neuropharmacol. 1989 Feb;12(1):1-13 PMID: 2540909
  9. Some puzzling pharmacological effects of monoamine oxidase inhibitors.
    Adv Biochem Psychopharmacol. 1972;5:393-408 PMID: 5066229
  10. Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid.
    Neuropharmacology. 1988 Apr;27(4):409-15 PMID: 2901673
  11. Anticonvulsant effects of some inhibitory neurotransmitter amino acids.
    Neurochem Res. 1983 Mar;8(3):291-302 PMID: 6134243
  12. Mechanism of anion permeation through channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal neurones.
    J Physiol. 1987 Apr;385:243-86 PMID: 2443667
  13. Rat brain folate identification.
    J Neurochem. 1976 Aug;27(2):409-13 PMID: 965984
  14. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.
    Br J Pharmacol. 1992 Jan;105(1):59-62 PMID: 1596690
  15. The effects of milacemide on item and source memory.
    Clin Neuropharmacol. 1992 Apr;15(2):114-9 PMID: 1591737
  16. Some observations upon a new inhibitor of monoamine oxidase in brain tissue.
    Biochem Pharmacol. 1968 Jul;17(7):1285-97 PMID: 5659776
  17. Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats.
    J Pharmacol Exp Ther. 1989 May;249(2):601-8 PMID: 2724142
  18. Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses.
    Neurochem Res. 1981 Dec;6(12):1309-17 PMID: 6122166
  19. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography.
    Clin Chem. 1982 Mar;28(3):527-31 PMID: 7067099
  20. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
    J Neurochem. 1988 Apr;50(4):1011-6 PMID: 3346666
  21. Monitoring the effect of a tryptophan load on brain indole metabolism in freely moving rats by simultaneous cerebrospinal fluid sampling and brain dialysis.
    J Neurochem. 1985 Apr;44(4):1266-73 PMID: 2579207
  22. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine.
    Eur J Pharmacol. 1990 Jun 21;182(1):109-15 PMID: 2119308
  23. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
    Arch Gerontol Geriatr. 1986 Oct;5(3):165-81 PMID: 3541816
  24. A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome.
    Mov Disord. 1991;6(1):73-5 PMID: 2005926
  25. The distribution of glycine in cat spinal cord and roots.
    Life Sci. 1965 Nov;4(21):2075-83 PMID: 5866625
  26. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.
    Am J Physiol. 1971 Dec;221(6):1629-39 PMID: 5124307
  27. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine.
    J Pharmacol Toxicol Methods. 1992 Aug;28(1):21-8 PMID: 1392055
  28. Double-blind study of milacemide in hospitalized therapy-resistant patients with epilepsy.
    Epilepsia. 1986 May-Jun;27(3):255-62 PMID: 3516669
  29. Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brain.
    Life Sci. 1983 Aug 8;33(6):533-41 PMID: 6888183
  30. Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases.
    Science. 1985 Mar 22;227(4693):1496-9 PMID: 2858129
  31. Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography.
    J Chromatogr. 1991 Apr 19;565(1-2):357-62 PMID: 1874879
  32. Pectineus Muscle and its Nerve-Supply.
    J Anat Physiol. 1891 Oct;26(Pt 1):43-7 PMID: 17231955
  33. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.
    Pharmacol Biochem Behav. 1989 Dec;34(4):823-8 PMID: 2516327
  34. Glycine potentiates the NMDA response in cultured mouse brain neurons.
    Nature. 1987 Feb 5-11;325(6104):529-31 PMID: 2433595
  35. Glycine therapy of schizophrenia.
    Biol Psychiatry. 1988 Jan 15;23(2):210-1 PMID: 3334889
  36. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex.
    J Pharmacol Exp Ther. 1984 Apr;229(1):44-50 PMID: 6707947
  37. Therapeutic trial with glycine in myoclonus.
    Mov Disord. 1988;3(3):222-32 PMID: 3057352
  38. Effect of milacemide, a glycinamide derivative, on the rat brain gamma-aminobutyric acid system.
    Biochem Pharmacol. 1983 Sep 15;32(18):2751-5 PMID: 6414480
  39. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
    J Neurochem. 1989 Oct;53(4):1109-16 PMID: 2769256
Article Info
Journal
British journal of pharmacology
Abbr.
Br J Pharmacol
ISSN
0007-1188
Published
1993-04-00
Pages
1117-24
Language
English
Region
England
NLM ID
7502536
PMCID
PMC1908144
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]